• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

522 Postmarket Surveillance Studies

  • Print
  • Share
  • E-mail
  • In May 2008, the oversight responsibility of the 522 Postmarket Surveillance Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH). DEPI continues to build the 522 program.
  • The 522 Postmarket Surveillance Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated under section 522 of the Federal Food, Drug and Cosmetic Act. The program helps ensure that well-designed 522 postmarket surveillance (PS) studies are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated internal tracking system that efficiently identifies the reporting status of active 522 PS studies based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all 522 PS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each 522 PS study. The webpage displays general information regarding each study, as well as the overall study status (based on protocol-driven timelines and adequacy of the data) and the applicant's reporting status for each submission due.


Contact Information

Nathan S. Ivey, PhD
Scientific Project Manager, 522 Postmarket Surveillance (PS) Studies Program
Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993-0002

Phone: (301) 796-7033
Fax: (301) 847-8140

OVA1 Performance in Pre and Post Menopausal Women

Suggest Enhancement / Report Issue | Export to ExcelExport to Excel
Study Status
PS110001 OVA1 Performance in Pre and Post Menopausal Women 03/15/2012 Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21 Progress Inadequate K081754

OVA1 Performance in Pre and Post Menopausal Women Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
6 month report 09/13/2012 09/13/2012 On Time
1 yr report 03/14/2013 03/14/2013 On Time
18 month report 09/12/2013 09/13/2013 Overdue/Received
2 yr report 03/15/2014 03/18/2014 Overdue/Received
3 yr report 03/15/2015 03/16/2015 Overdue/Received
4 yr report 03/14/2016    
5 yr report 03/14/2017    
Final report 03/14/2018